|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
2004
|
|
gptkbp:ATCCode
|
gptkb:N03AX16
|
|
gptkbp:bioavailability
|
≥90%
|
|
gptkbp:brand
|
gptkb:Pregabalin_Accord
gptkb:Lyrica
Lecaent
Rewisca
|
|
gptkbp:canCauseWithdrawal
|
yes
|
|
gptkbp:chemicalFormula
|
C8H17NO2
|
|
gptkbp:contraindication
|
hypersensitivity to pregabalin
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_V_(US)
|
|
gptkbp:drugClass
|
analgesic
benzodiazepine
anticonvulsant
|
|
gptkbp:eliminationHalfLife
|
6.3 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
capsule
oral solution
extended-release tablet
|
|
gptkbp:genericName
|
gptkb:pregabalin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lyrica
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:CNS_depressants
opioids
|
|
gptkbp:lactation
|
excreted in breast milk
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
modulates calcium channels
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:overdoseSymptoms
|
confusion
seizures
agitation
somnolence
|
|
gptkbp:patentExpired
|
2018 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:pregnancyRisk
|
potential fetal harm
|
|
gptkbp:proteinBinding
|
<1%
|
|
gptkbp:riskOfMisuse
|
low
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
dizziness
blurred vision
weight gain
drowsiness
dry mouth
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
epilepsy
peripheral neuropathy
fibromyalgia
|
|
gptkbp:bfsParent
|
gptkb:Pfizer
|
|
gptkbp:bfsLayer
|
4
|